Corporate Retrospective 2007: New Objective
On behalf of New Objective, I extend my warm congratulations to LCGC in this, its historic 25th-year anniversary. New Objective shares in celebration, as we reach our own 10-year milestone in 2007. Back in 1997 when New Objective made its debut as a two-person corporation, personal risks were high, and the practice of applying nanobore reverse-phase chromatography and (nano)electrospray-enabled mass spectrometry was in its infancy. This past decade enabled us to participate in the growth, acceptance, and demand for both ion-trap and quadrupole time-of-flight mass spectrometry as definitive vehicles for high-sensitivity protein characterization and the now burgeoning field of proteomics.
On behalf of New Objective, I extend my warm congratulations to LCGC in this, its historic 25th-year anniversary. New Objective shares in celebration, as we reach our own 10-year milestone in 2007. Back in 1997 when New Objective made its debut as a two-person corporation, personal risks were high, and the practice of applying nanobore reverse-phase chromatography and (nano)electrospray-enabled mass spectrometry was in its infancy. This past decade enabled us to participate in the growth, acceptance, and demand for both ion-trap and quadrupole time-of-flight mass spectrometry as definitive vehicles for high-sensitivity protein characterization and the now burgeoning field of proteomics.
Our clientele has expanded from a handful of passionate, dedicated analysts to thousands of multidisciplinary professionals across the life sciences, including chemists, biochemists, microbiologists, geneticists, enzymologists, and medical professionals. Global recognition of mass spectrometry as an effective technique goes hand-in-hand with the success of nanobore-scale, reverse-phase chromatography in generating superior separations from complex biological matrices. We have observed a wide-scale preference toward 75 μm columns ("the new 4.6"!), and enjoy the benefits of next-generation LC pumps that afford reliable split-free operation. Nanobore LC–MS systems now operate 24/7, while providing sub-femtomole limits of detection.
Significant technical challenges confront the next chapter of our evolving industry; much of this incorporates an emerging shift from qualitative analysis — asking, "What is there?"— to quantitative biomarker study — asking "How much is there?" Our success in this transition warrants further refinement of both nanobore chromatography and electrospray ionization mass spectrometry. Automated strategies for sample-handling, preparation, delivery, ionization, and analysis will become increasingly important as we forge ahead.
Gary Valaskovic
Gary Valaskovic, Ph.D.
President & Co-founder
New Objective, Inc.
TD-GC–MS and IDMS Sample Prep for CRM to Quantify Decabromodiphenyl Ether in Polystyrene Matrix
April 26th 2024At issue in this study was the certified value of decabromodiphenyl ether (BDE 209) in a polystyrene matrix CRM relative to its regulated value in the EU Restriction of Hazardous Substances Directive.
High-Throughput 4D TIMS Method Accelerates Lipidomics Analysis
April 25th 2024Ultrahigh-pressure liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) had been previously proposed for untargeted lipidomics analysis, but this updated approach was reported by the authors to reduce run time to 4 min.
Inside the Laboratory –– Women in Separation Science Edition
April 25th 2024Inside the Laboratory is a joint series with LCGC and Spectroscopy, profiling analytical scientists and their research groups at universities all over the world. This series spotlights the current chromatographic and spectroscopic research their groups are conducting, and the importance of their research in analytical chemistry and specific industries. In this “Inside the Laboratory –– Women in Separation Science” special edition PDF, we profile four industry leaders and the impact that their research is having in specific fields such as environmental analysis, forensics, national security, and drug development.
